![The Diagnostics Pipeline: FDA Launches Pilot for Cancer Companion Diagnostic LDTs](https://www.g2intelligence.com/wp-content/uploads/2023/07/August23.DTET_.NewProductsPipeline.formerlyFDAWatch-iStock-1100x800-1-1080x675.jpg)
The Diagnostics Pipeline: FDA Launches Pilot for Cancer Companion Diagnostic LDTs
New program aims to provide greater transparency on the recommended performance characteristics of such tests.
New program aims to provide greater transparency on the recommended performance characteristics of such tests.
Federal lawmakers have renewed efforts to pass legislation ensuring Medicare coverage of multi-cancer early detection (MCED) tests.
Key approvals announced in June represented important steps forward for the lab testing industry.
Although PRS technology and adoption still have a way to go, it is progressing quickly, especially in the cancer and oncology space.
New research suggests that the call to rein in low-value prostate cancer screening seems to be falling on deaf ears.